Science Explorer Back to mapMap
Discussion
Institution · Chris O’Brien Lifehouse

Most cited papers from Chris O’Brien Lifehouse

Chris O’Brien Lifehouse

What are the most cited papers from Chris O’Brien Lifehouse?

The most cited paper from Chris O’Brien Lifehouse is "Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer" (Leena Gandhi et al., 2018), with 6,764 citations. Next come "Pembrolizumab versus Ipilimumab in Advanced Melanoma" (5,968) and "Nivolumab in Previously Untreated Melanoma without BRAF Mutation" (5,431).

Showing 50 of 60 papers. Every paper with more than 183 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer Leena Gandhi et al. · New England Journal of Medicine Open access 16 Apr 2018 6,764
2 Pembrolizumab versus Ipilimumab in Advanced Melanoma Caroline Robert et al. · New England Journal of Medicine Open access 19 Apr 2015 5,968
3 Nivolumab in Previously Untreated Melanoma without BRAF Mutation Caroline Robert et al. · New England Journal of Medicine Open access 16 Nov 2014 5,431
4 Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study Aurélien Marabelle et al. · The Lancet Oncology Open access 10 Sep 2020 2,600
5 A single-cell and spatially resolved atlas of human breast cancers Sunny Z. Wu et al. · Nature Genetics Open access Sep 2021 1,918
6 Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer Ian D. Davis et al. · New England Journal of Medicine 2 Jun 2019 1,649
7 Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) Jacob Schachter, Antoni Ribas, Georgina Venetia Long et al. · The Lancet 16 Aug 2017 1,256
8 Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial Keunchil Park et al. · The Lancet Oncology 12 Apr 2016 1,192
9 Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer Shirish M. Gadgeel et al. · Journal of Clinical Oncology Open access 9 Mar 2020 1,181
10 Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study Caroline Robert, Antoni Ribas, Jacob Schachter et al. · The Lancet Oncology Open access 22 Jul 2019 1,179
11 [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial Michael S. Hofman et al. · The Lancet Feb 2021 1,154
12 Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci The Profile Study et al. · Nature Genetics Open access192 authors 8 Jun 2018 1,025
13 Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study Nico van Zandwijk, Nick Pavlakis, Steven Chuan-Hao Kao et al. · The Lancet Oncology 2 Sep 2017 730
14 ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer Michelle van Geldermalsen, Qian Wang, Rajini Nagarajah et al. · Oncogene Open access 12 Oct 2015 593
15 The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non–Small Cell Lung Cancer Roy Martin Bremnes, Lill‐Tove Busund, Thomas L. Kilvær et al. · Journal of Thoracic Oncology Open access Feb 2016 543
16 NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial Sylvie Bonvalot et al. · The Lancet Oncology Open access 8 Jul 2019 537
17 Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial Luis G Paz-Ares, E.H. Tan, Kenneth John O'Byrne et al. · Annals of Oncology Open access 30 Jan 2017 528
18 Hospital-based interventions: a systematic review of staff-reported barriers and facilitators to implementation processes Liesbeth Geerligs, Nicole Marion Rankin, Heather L. Shepherd et al. · Implementation Science ReviewOpen access 22 Feb 2018 524
19 Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction David V. Conti et al. · Nature Genetics ReviewOpen access231 authors 2021 511
20 Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial Paolo A. Ascierto et al. · The Lancet Oncology 27 Mar 2017 507
21 Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial William D. Tap et al. · The Lancet Open access 19 Jun 2019 497
22 FAK signaling in human cancer as a target for therapeutics Brian Y. Lee, Paul Timpson, Lisa Glen Horvath et al. · Pharmacology & Therapeutics Open access 12 Oct 2014 461
23 Stromal cell diversity associated with immune evasion in human triple‐negative breast cancer Sunny Z. Wu et al. · The EMBO Journal Open access 13 Aug 2020 460
24 Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer Aurélie Cazet et al. · Nature Communications Open access 18 Jul 2018 450
25 Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies Hyun Cheol Chung et al. · Journal of Thoracic Oncology Open access 20 Dec 2019 445
26 Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189 Delvys Rodríguez‐Abreu et al. · Annals of Oncology Open access 22 Apr 2021 428
27 Global Disparities of Cancer and Its Projected Burden in 2050 Habtamu Mellie Bizuayehu, Kedir Yimam Ahmed, Getiye Dejenu Kibret et al. · JAMA Network Open Open access 5 Nov 2024 400
28 ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Alice Tsang Shaw, Benjamin J. Solomon, Benjamin Besse et al. · Journal of Clinical Oncology Open access 20 Mar 2019 388
29 Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions Caicun Zhou et al. · New England Journal of Medicine 21 Oct 2023 376
30 Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial Alice Tsang Shaw, Benjamin J. Solomon, Rita Chiari et al. · The Lancet Oncology 25 Oct 2019 360
31 Hyperbaric oxygen therapy for late radiation tissue injury Michael H Bennett, John J. Feldmeier, Neil B. Hampson et al. · Cochrane Database of Systematic Reviews Open access 28 Apr 2016 359
32 Bisphosphonates and other bone agents for breast cancer Brent O’Carrigan, Matthew H. Wong, Melina L Willson et al. · Cochrane Database of Systematic Reviews Open access 30 Oct 2017 359
33 Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy Paolo A. Ascierto et al. · JAMA Oncology Open access 26 Oct 2018 347
34 Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study Luis G Paz-Ares et al. · Journal of Clinical Oncology Open access 23 Jan 2023 336
35 Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC Roy S. Herbst, Edward B. Garon, Dong‐Wan Kim et al. · Journal of Thoracic Oncology Open access 25 May 2021 321
36 Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition Jenny Lee, Elena Shklovskaya, Su Yin Lim et al. · Nature Communications Open access 20 Apr 2020 308
37 PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma Wendy A. Cooper, Trần Nam Thắng, Ricardo E. Vilain et al. · Lung Cancer 18 May 2015 305
38 PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial James Patrick Buteau et al. · The Lancet Oncology Open access 16 Oct 2022 291
39 Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study Michael Joseph Boyer et al. · Journal of Clinical Oncology Open access 29 Jan 2021 261
40 Human CD8+ T cell cross-reactivity across influenza A, B and C viruses Marios Koutsakos et al. · Nature Immunology Open access 18 Feb 2019 250
41 Circulating T FH cells, serological memory, and tissue compartmentalization shape human influenza-specific B cell immunity Marios Koutsakos et al. · Science Translational Medicine 14 Feb 2018 248
42 Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial Georgina Venetia Long et al. · The Lancet Oncology Open access 17 Jul 2017 248
43 Fear of cancer recurrence: a theoretical review and novel cognitive processing formulation Joanna Elizabeth Fardell, Belinda Thewes, Jane Turner et al. · Journal of Cancer Survivorship 18 Jan 2016 247
44 HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy Helena Alexandra Yu et al. · Journal of Clinical Oncology Open access 10 Sep 2023 245
45 Programmed death ligand 1 expression in triple‐negative breast cancer is associated with tumour‐infiltrating lymphocytes and improved outcome Rhiannon K. Beckers et al. · Histopathology 20 Nov 2015 244
46 Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial Lorraine A. Chantrill et al. · Clinical Cancer Research 21 Apr 2015 243
47 Clinical Development of TargomiRs, a miRNA Mimic-Based Treatment for Patients with Recurrent Thoracic Cancer Glen Reid, Steven Kao, Nick Pavlakis et al. · Epigenomics Open access 17 May 2016 241
48 Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma Caroline Robert et al. · Journal of Clinical Oncology Open access 30 Sep 2020 239
49 Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer Alexander Edward Dela Cruz Drilon et al. · New England Journal of Medicine Open access 10 Jan 2024 236
50 Understanding the extracellular vesicle surface for clinical molecular biology Susannah M. Hallal, Ágota Tűzesi, Georges E. Grau et al. · Journal of Extracellular Vesicles Open access Oct 2022 235

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.